| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ustekinumab, ATC L04AC05 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fampridin, ATC N07XX07 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tacrolimus, ATC L04AD02 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Financial leasing services – Fahrradleasing Framework | Financial leasing services, Non-motorised bicycles, +1 | - | Jul 14, 2026 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Macrogol in Komb. (ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte oder nach Anlage 5 AM-RL G-BA verordnungsfähige Medizinprodukte), ATC A06AD6 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Estradiol, ATC G03CA03 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ribociclib, ATC L01EF02 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Macrogol (ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte oder nach Anlage 5 AM-RL G-BA verordnungsfähige Medizinprodukte), ATC A06AD15 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dolutegravir und Rilpivirin, ATC J05AR21 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Bimatoprost, ATC S01EE03 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Rebif(R), ATC L03AB07 Framework | Pharmaceutical products | - | Jun 3, 2028 | Jun 14, 2026 | Active |
| Germany – Medical aids – Verhandlungsabsicht Vertrag nach § 127 Abs. 1 SGB V der AOK Bayern über die Versorgung mit Teststreifen Framework | Medical aids | - | Jul 31, 2026 | May 19, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nitisinon, ATC A16AX04 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Dysport(R)/Dysline(R), ATC M03AX21 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Triptorelin, ATC L02AE04 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lanthan(III)-carbonat, ATC V03AE03 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Perampanel, ATC N03AX22 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tacrolimus, ATC D11AH01 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fondaparinux, ATC B01AX05 Framework | Pharmaceutical products | - | May 3, 2028 | May 17, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Doravirin, ATC J05AG06 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamivudin, Abacavir und Dolutegravir, ATC J05AR13 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cabotegravir in der Darreichungsform Depot-Injektionssuspension, ATC J05AJ04 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ertugliflozin, ATC A10BK04 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamivudin, Tenofovirdisoproxil und Doravirin, ATC J05AR24 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dolutegravir, ATC J05AJ03 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamivudin und Dolutegravir, ATC J05AR25 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Oxycodon und Naloxon, ATC N02AA55 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Valproinsäure in nicht retardierter Darreichungsform, ATC N03AG01 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rilpivirin in der Darreichungsform Depot-Injektionssuspension, ATC J05AG05 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vilanterol und Umeclidiniumbromid, ATC R03AL03 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dimethylfumarat, ATC L04AX07 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sitagliptin und Ertugliflozin, ATC A10BD24 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Alitretinoin, ATC D11AH04 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Avonex(R), ATC L03AB07 Framework | Pharmaceutical products | - | Apr 3, 2028 | Apr 14, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Clindamycin und Benzoylperoxid, ATC D10AF54 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Clobetasol, ATC D07AD01 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nintedanib, ATC L01EX09 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Levothyroxin-Natrium, ATC H03AA01 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene zur subkutanen Immuntherapie, ATC V01AA02 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Atovaquon, ATC P01AX06 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Safinamid, ATC N04BD03 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Daridorexant, ATC N05CJ03 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eptinezumab, ATC N02CD05 Framework | Pharmaceutical products | - | Mar 3, 2028 | Mar 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cladribin, ATC L04AA40 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fremanezumab, ATC N02CD03 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Filgrastim, ATC L03AA02 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Chinin, ATC M09AA02 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Diclofenac, ATC D11AX18 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Brodalumab, ATC L04AC12 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fingolimod in der Wirkstärke 0,25 mg, ATC L04AE01 Framework | Pharmaceutical products | - | Feb 3, 2028 | Feb 15, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Repaglinid, ATC A10BX02 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Etonogestrel und Ethinylestradiol (Vaginalring mit Gestagenen und Estrogenen), ATC G02BB01 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Calcipotriol und Betamethason ausgenommen in den Darreichungsformen Salben und Gele, ATC D05AX22 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Minoxidil, ATC C02DC01 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Betahistin, ATC N07CA01 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aclidiniumbromid, ATC R03BB05 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pamidronsäure, ATC M05BA03 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sulpirid, ATC N05AL01 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Xipamid, ATC C03BA10 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fusidinsäure, ATC D06AX01 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Hydrocortison in der Wirkstärke 10mg in den Darreichungsformen Tabletten und Filmtabletten, ATC H02AB09 Framework | Pharmaceutical products | - | Jan 3, 2028 | Jan 13, 2026 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fentanyl in der Darreichungsform Sublingualtabletten und Lutschtabletten, ATC N02AB03 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene, ATC V01AA03 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tiaprid, ATC N05AL03 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tobramycin, ATC J01GB01 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Urapidil, ATC C02CA06 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Teriparatid, ATC H05AA02 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Flecainid, ATC C01BC04 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene, ATC V01AA05 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Injektionslösung in einer Fertigspritze, ATC L03AX13 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol, ATC S01ED01 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene mit der Fertigarzneimittelbezeichnung Grazax(R), ATC V01AA02 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Alfacalcidol, ATC A11CC03 Framework | Pharmaceutical products | - | Dec 3, 2027 | Dec 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Relugolix, ATC L02BX04 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Guanfacin, ATC N06BA21 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pazopanib, ATC L01EX03 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aflibercept, ausgenommen 114,3 mg/ml, ATC S01LA05 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fluorouracil, ATC D11AF05 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Testosteron in der Darreichungsform Injektionslösung, ATC G03BA03 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Beclometason dipropionat, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/4,91µg, ATC R03AK08 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Fertigspritze, ATC S01LA04 Framework | Pharmaceutical products | - | Nov 3, 2027 | Nov 16, 2025 | Active |
| Germany – Medical consumables – Open House Vertrag über die Versorgung mit patientenindividuell verordneten Verbandmitteln und sonstigen Produkten der Wundbehandlung § 31 Abs. 1a SGB V und Medizinprodukten mit Verbandmittelcharakter Framework | Medical consumables | - | Dec 20, 2029 | Nov 12, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risankizumab, ATC L04AC18 Framework | Pharmaceutical products | - | Oct 3, 2027 | Oct 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Allergenextrakte aus Gräserpollen zur sublingualen Anwendung, Handelsbezeichnung Oralair(R), ATC V01AA02 Framework | Pharmaceutical products | - | Oct 3, 2027 | Oct 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pegfilgrastim, ATC L03AA13 Framework | Pharmaceutical products | - | Oct 3, 2027 | Oct 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Natalizumab in der Darreichungsform Konz.z.Herst.e.Inf.-Lsg. , ATC L04AG03 Framework | Pharmaceutical products | - | Oct 3, 2027 | Oct 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Paliperidon, in 3-Monats-Depot-Darreichungsformen, ATC N05AX13 Framework | Pharmaceutical products | - | Sep 3, 2027 | Sep 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Brinzolamid, ATC S01ED67 Framework | Pharmaceutical products | - | Sep 3, 2027 | Sep 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Octreotid, ATC H01CB02 Framework | Pharmaceutical products | - | Sep 3, 2027 | Sep 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tiotropiumbromid, in der Darreichungsform Inhalationslösung (Respimat(R)), ATC R03BB04 Framework | Pharmaceutical products | - | Sep 3, 2027 | Sep 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Tafluprost, ATC S01ED70 Framework | Pharmaceutical products | - | Sep 3, 2027 | Sep 14, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Omalizumab, ATC R03DX05 Framework | Pharmaceutical products | - | Aug 3, 2027 | Aug 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dornase alfa (Desoxyribonuclease), ATC R05CB13 Framework | Pharmaceutical products | - | Aug 3, 2027 | Aug 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Leuprorelin, ATC L02AE02 Framework | Pharmaceutical products | - | Aug 3, 2027 | Aug 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eltrombopag, ausgeschl. Anwendungsgebiet schwere aplastische Anämie in der Fachinformation, es sei denn, der Hersteller genießt hierfür Patenschutz, ATC B02BX05 Framework | Pharmaceutical products | - | Aug 3, 2027 | Aug 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Anakinra, ATC L04AC03 Framework | Pharmaceutical products | - | Aug 3, 2027 | Aug 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Colchicin, ATC M04AC01 Framework | Pharmaceutical products | - | Aug 3, 2027 | Aug 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Aripiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12 (Kopie) Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 24, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Adalimumab, ATC L04AB04 Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01 Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01 Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Amifampridin, ATC N07XX05 Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Airpiprazol in der Darreichungsform Depot-Injektionssuspension, ATC N05AX12 Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pyridostigmin, ATC N07AA02 Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 13, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Blutzuckerteststreifen Framework | Pharmaceutical products | - | Jul 3, 2027 | Jul 10, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Budesonid, ATC A07EA06 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tofacitinib, ATC L04AF01 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Brinzolamid und Brimonidin, ATC S01EC24 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol, Glycopyrroniumbromid und Beclometason, ATC R03AL09 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin zeta, ATC B03AX01 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Epinephrin, ATC C01CA24 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Peginterferon beta-1a, ATC L03AB13 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tolvaptan, ausgenommen Arzneimittel mit einheitlichen Wirkstärken, ATC G04BX21 Framework | Pharmaceutical products | - | Jun 3, 2027 | Jun 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Eribulin, ATC L01XX41 Framework | Pharmaceutical products | - | May 16, 2027 | May 19, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sunitinib, ATC L01EX01 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Apremilast, ATC L04AA32 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Axitinib, ATC L01EK01 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol, Glycopyrroniumbromid und Budesonid, ATC R03AL11 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eisen(III)-Derisomaltose, ATC B03AC08 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eisen(III)hydroxid-Polymaltose-Komplex, ATC B03AC01 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ticagrelor, ATC B01AC24 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Liraglutid, ATC A10BJ02 Framework | Pharmaceutical products | - | May 5, 2027 | May 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Trazodon, ATC N06AX05 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Trastuzumab, ATC L01FD01 Framework | Pharmaceutical products | - | Apr 16, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Betamethason und Fusidinsäure, ATC D07CC01 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Bevacizumab, ATC L01FG01 Framework | Pharmaceutical products | - | Apr 16, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Rituximab, ATC L01FA01 Framework | Pharmaceutical products | - | Apr 16, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tolterodin, ATC G04BD07 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ibuprofen, ATC M01AE01 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tamsulosin und Dutasterid, ATC G04CA52 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glatirameracetat in der Darreichungsform Fertigpen, ATC L03AX13 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Posaconazol, ATC J02AC04 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Roxithromycin, ATC J01FA06 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamotrigin, ATC N03AX09 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Certolizumab pegol, ATC L04AB05 Framework | Pharmaceutical products | - | Apr 5, 2027 | Apr 15, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Umeclidiniumbromid, ATC R03BB07 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vilanterol und Fluticasonfuroat, ATC R03AK10 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Aclidiniumbromid, ATC R03AL05 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Somatropin, ATC H01AC01 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Fluticason, ATC R03AK11 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Meropenem, ATC J01DH02 Framework | Pharmaceutical products | - | Mar 5, 2027 | Mar 18, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Fluticason und Azelastin, ATC R01AD28 Framework | Pharmaceutical products | - | Feb 5, 2027 | Feb 17, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Opipramol, ATC N06AA05 Framework | Pharmaceutical products | - | Feb 5, 2027 | Feb 17, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rotigotin, ATC N04BC09 Framework | Pharmaceutical products | - | Feb 5, 2027 | Feb 17, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Brinzolamid und Brimonidin, ATC S01EC24 Framework | Pharmaceutical products | - | Feb 5, 2027 | Feb 17, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06 Framework | Pharmaceutical products | - | Feb 5, 2027 | Feb 17, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nilotinib, ATC L01EA03 (ausgeschlossen Nilotinib dispergiert in Apfelmus, es sei denn, der Hersteller genießt hierfür Patentschutz) Framework | Pharmaceutical products | - | Jan 4, 2027 | Jan 21, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Goserelin, ATC L02AE03 Framework | Pharmaceutical products | - | Jan 5, 2027 | Jan 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Botulinumtoxin Typ A, Fertigarzneimittelbezeichnung Xeomin(R), ATC M03AX21 Framework | Pharmaceutical products | - | Jan 5, 2027 | Jan 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Colecalciferol, non RX, ausschließlich nach Anlage 1 AM-RL G-BA verordnungsfähige Produkte, ATC A11CC05 Framework | Pharmaceutical products | - | Jan 5, 2027 | Jan 16, 2025 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Buserelin, ATC L02AE01 Framework | Pharmaceutical products | - | Dec 5, 2026 | Dec 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tapentadol in den nicht retardierten Darreichungsformen, ATC N02AX06 Framework | Pharmaceutical products | - | Dec 5, 2026 | Dec 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Trientin, ATC A16AX12 Framework | Pharmaceutical products | - | Dec 5, 2026 | Dec 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Carbamazepin, ATC N03AF01 Framework | Pharmaceutical products | - | Dec 5, 2026 | Dec 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lipegfilgrastim, ATC L03AA14 Framework | Pharmaceutical products | - | Nov 5, 2026 | Nov 17, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tocilizumab, ATC L04AC07 Framework | Pharmaceutical products | - | Nov 5, 2026 | Nov 17, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Flupentixol, ATC N05AF01 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Melatonin, ausgenommen Darreichungsform 2 mg Retardtabletten, ATC N05CH01 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Chlortalidon, ATC C03BA04 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rituximab, ATC L01FA01 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Trastuzumab, ATC L01FD01 Framework | Pharmaceutical products | - | Oct 5, 2026 | Oct 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eltrombopag, ATC B02BX05 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naproxen, ATC M01AE02 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Etanercept, ATC L04AB01 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Piribedil, ATC N04BC08 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Denosumab, ATC M05BX04 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lopinavir und Ritonavir, ATC J05AR10 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rasagilin, ATC N04BD02 Framework | Pharmaceutical products | - | Sep 5, 2026 | Sep 16, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Latanoprost, ATC S01ED61 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lisdexamfetamin, ATC N06BA12 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Miglustat, ATC A16AX06 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Raltegravir, ATC J05AJ01 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Treprostinil, ATC B01AC21 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lacosamid (ausgenommen Darreichungsform Filmtabletten), ATC N03AX18 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Pomalidomid, ATC L04AX06 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Mesalazin, ATC A07EC02 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Glyceroltrinitrat, ATC C01DA02 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Febuxostat, ATC M04AA03 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Telmisartan, ATC C09CA07 Framework | Pharmaceutical products | - | Aug 5, 2026 | Aug 15, 2024 | Active |
| Germany – Hospital and related services – Open House Verfahren zum Abschluss von Verträgen zur besonderen interdisziplinären und intersektoralen Versorgung von Patienten mit familiär erhöhtem Risiko für Brust- und Eierstockkrebs Framework | Hospital and related services | - | Nov 3, 2033 | Nov 7, 2023 | Active |